Stoke Therapeutics (NASDAQ:STOK) Rating Reiterated by Needham & Company LLC

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating reiterated by investment analysts at Needham & Company LLC in a report issued on Monday, Benzinga reports. They currently have a $22.00 price target on the stock. Needham & Company LLC’s price target would indicate a potential upside of 84.25% from the company’s current price.

Several other equities research analysts have also recently weighed in on the company. TD Cowen raised Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 26th. Canaccord Genuity Group upped their target price on Stoke Therapeutics from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, March 26th. JPMorgan Chase & Co. increased their target price on Stoke Therapeutics from $6.00 to $13.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 26th. HC Wainwright restated a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a report on Tuesday, March 26th. Finally, Wedbush lifted their price target on shares of Stoke Therapeutics from $13.00 to $17.00 and gave the company an “outperform” rating in a research note on Tuesday, March 26th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $20.57.

Stoke Therapeutics Price Performance

Shares of NASDAQ:STOK opened at $11.94 on Monday. The company has a market capitalization of $622.31 million, a P/E ratio of -5.04 and a beta of 0.82. Stoke Therapeutics has a 1-year low of $3.35 and a 1-year high of $16.40. The firm’s 50 day simple moving average is $10.23 and its two-hundred day simple moving average is $6.68.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Monday, March 25th. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.02. The company had revenue of $2.80 million for the quarter, compared to the consensus estimate of $3.70 million. On average, sell-side analysts anticipate that Stoke Therapeutics will post -2.28 earnings per share for the current fiscal year.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 11,150 shares of the company’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total transaction of $68,015.00. Following the completion of the sale, the chief executive officer now owns 69,350 shares in the company, valued at $423,035. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, CEO Edward M. Md Kaye sold 11,150 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total value of $68,015.00. Following the transaction, the chief executive officer now directly owns 69,350 shares in the company, valued at approximately $423,035. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Stephen J. Tulipano sold 4,116 shares of the company’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total value of $25,107.60. Following the sale, the chief financial officer now owns 20,746 shares of the company’s stock, valued at $126,550.60. The disclosure for this sale can be found here. Insiders have sold a total of 3,622,741 shares of company stock valued at $41,935,115 over the last ninety days. 11.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Chase Investment Counsel Corp purchased a new stake in Stoke Therapeutics during the first quarter valued at approximately $279,000. BNP Paribas Financial Markets lifted its holdings in shares of Stoke Therapeutics by 86.2% during the 1st quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock valued at $193,000 after purchasing an additional 6,636 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Stoke Therapeutics in the 1st quarter worth $1,224,000. Seven Grand Managers LLC purchased a new position in Stoke Therapeutics during the 1st quarter worth $405,000. Finally, Birchview Capital LP increased its position in Stoke Therapeutics by 147.1% during the 4th quarter. Birchview Capital LP now owns 210,000 shares of the company’s stock valued at $1,105,000 after buying an additional 125,000 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.